NORD President Abbey Meyers with Senator Christopher Dodd (D-CT)
|
NORD Board Members Frank Sasinowski and Josephine Grima, PhD, with
Janet Woodcock, MD (center), Acting Deputy Commissioner for Operations,
U.S. Food and Drug Administration
|
Fredric Price, Chairman and CEO of BioMarin, with David Meeker, President
of Lysosomal Storage Disease Therapeutics at Genzyme
|
Karen Ignagni, President & CEO of America's Health Insurance Plans
|
Stephen C. Groft, PharmD, Director of the Office of Rare Diseases,
NIH, and Edward Boyer, CEO of Mercy Medical Airlift and NORD Board Member
|
NORD Board Member Jayne Gershkowitz
|
Kathleen Jaeger, President, Generic Pharmaceutical Association
|
Maria Hardin, NORD staff, with Fredric Price, BioMarin Chairman and
CEO
|
James Broatch, Chairman of NORD's Board of Directors, and NORD Board
Member Estelle Benson
|
Jean Campbell, NORD staff, with William Gunnarson of Orphan Medical
and Milton Ellis of Rare Disease Therapeutics
|
NORD staff members and volunteers
|
Brad Gary, Vice President of Government Affairs, Allergan
|
Sen. Dodd talked of upcoming issues
|
Michael Losow of the Biotechnology Industry Organization (BIO)
|
Giovanna Spinella, MD, (left) and Henrietta Hyatt-Knorr (right), both
of the NIH Office of Rare Diseases, with Donna Bolton of NORD's staff
|
Read about events on Capitol Hill, funding for rare-disease research, and other topics of interest from NORD's office in Washington, DC.
